Scroll

dimenhydrinate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
N-methylated xanthine derivatives	901	523-87-5

Description:

Molecule	Description
Synonyms: dimenhydrinate andramine chloranautine diamarin diphenhydramine 8-chlorotheophyllinate diphenhydrinate dramamine menhydrinate theohydramine	A drug combination that contains diphenhydramine and theophylline. It is used for treating VERTIGO, MOTION SICKNESS, and NAUSEA associated with PREGNANCY. Molecular weight: 469.97 Formula: C24H28ClN5O3 CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

dimenhydrinate
andramine
chloranautine
diamarin
diphenhydramine 8-chlorotheophyllinate
diphenhydrinate
dramamine
menhydrinate
theohydramine

A drug combination that contains diphenhydramine and theophylline. It is used for treating VERTIGO, MOTION SICKNESS, and NAUSEA associated with PREGNANCY.

Molecular weight: 469.97
Formula: C24H28ClN5O3
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

Dose	Unit	Route
0.30	g	O
0.30	g	R

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
May 31, 1972	FDA	ALRA

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Urine abnormality	431.77	14.80	168	43954	6851	63438049
Lymphocyte count decreased	334.57	14.80	227	43895	30030	63414870
Urine leukocyte esterase positive	275.70	14.80	101	44021	3478	63441422
White blood cells urine positive	210.23	14.80	92	44030	5066	63439834
Red blood cells urine positive	207.13	14.80	79	44043	3047	63441853
Blood urine present	205.56	14.80	129	43993	14940	63429960
Enthesopathy	199.01	14.80	104	44018	8510	63436390
Tongue disorder	181.65	14.80	105	44017	10475	63434425
Urinary sediment present	180.23	14.80	65	44057	2138	63442762
Tenosynovitis	170.56	14.80	111	44011	13684	63431216

Showing 1 to 10 of 282 entries

Previous1 2 3 4 5…29Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Aplastic anaemia	310.69	17.11	121	12586	9595	34934629
Tenosynovitis	160.60	17.11	61	12646	4509	34939715
Enthesopathy	160.05	17.11	61	12646	4552	34939672
Tongue disorder	130.99	17.11	55	12652	5284	34938940
Febrile neutropenia	127.52	17.11	199	12508	136650	34807574
C-reactive protein abnormal	119.80	17.11	60	12647	8650	34935574
Victim of child abuse	114.09	17.11	32	12675	895	34943329
Epidural lipomatosis	110.03	17.11	32	12675	1022	34943202
Respiratory depression	106.68	17.11	69	12638	16176	34928048
Mucosal inflammation	102.86	17.11	96	12611	38526	34905698

Showing 1 to 10 of 103 entries

Previous1 2 3 4 5…11Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Urine abnormality	471.50	13.72	186	54134	8033	79682035
Aplastic anaemia	405.92	13.72	212	54108	17693	79672375
Enthesopathy	335.34	13.72	162	54158	11446	79678622
Lymphocyte count decreased	324.06	13.72	264	54056	47025	79643043
Tenosynovitis	309.87	13.72	169	54151	15385	79674683
Tongue disorder	298.40	13.72	159	54161	13816	79676252
Urine leukocyte esterase positive	286.22	13.72	107	54213	3984	79686084
White blood cells urine positive	229.11	13.72	102	54218	5973	79684095
Blood parathyroid hormone decreased	225.29	13.72	120	54200	10416	79679652
Red blood cell sedimentation rate	214.89	13.72	95	54225	5470	79684598

Showing 1 to 10 of 342 entries

Previous1 2 3 4 5…35Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	R06AA11	RESPIRATORY SYSTEM ANTIHISTAMINES FOR SYSTEMIC USE ANTIHISTAMINES FOR SYSTEMIC USE Aminoalkyl ethers
ATC	R06AA61	RESPIRATORY SYSTEM ANTIHISTAMINES FOR SYSTEMIC USE ANTIHISTAMINES FOR SYSTEMIC USE Aminoalkyl ethers
CHEBI has role	CHEBI:37955	H1 receptor antagonists
CHEBI has role	CHEBI:50919	antiemetico
MeSH PA	D000932	Antiemetics
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D005765	Gastrointestinal Agents
MeSH PA	D018494	Histamine Agents
MeSH PA	D006633	Histamine Antagonists
MeSH PA	D006634	Histamine H1 Antagonists

Showing 1 to 10 of 12 entries

Previous1 2Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Nausea and vomiting	indication	16932000
Motion sickness	indication	37031009	DOID:2951
Vertigo	indication	399153001
Vomiting	indication	422400008
Nausea	indication	422587007
Prevention of Motion Sickness	indication
Prevention of Nausea and Vomiting	indication
Ménière's disease	off-label use	13445001	DOID:9849
Ocular hypertension	contraindication	4210003	DOID:9282
Hypophosphatemia	contraindication	4996001

Showing 1 to 10 of 32 entries

Previous1 2 3 4Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Histamine H1 receptor	GPCR	P35367	HRH1_HUMAN	ANTAGONIST	Ki	7.43	DRUG MATRIX	CHEMBL
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN		Ki	5.79	DRUG MATRIX
Sigma non-opioid intracellular receptor 1	Membrane receptor	Q99720	SGMR1_HUMAN		Ki	6.31	DRUG MATRIX
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN		Ki	5.70	DRUG MATRIX
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN		Ki	6.70	DRUG MATRIX
5-hydroxytryptamine receptor 2B	GPCR	P41595	5HT2B_HUMAN		Ki	5.96	DRUG MATRIX
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN		Ki	6.48	DRUG MATRIX
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN		Ki	5.60	DRUG MATRIX
Muscarinic acetylcholine receptor M1	GPCR	P11229	ACM1_HUMAN		Ki	6.96	DRUG MATRIX
Muscarinic acetylcholine receptor M2	GPCR	P08172	ACM2_HUMAN		Ki	6.79	DRUG MATRIX

Showing 1 to 10 of 16 entries

Previous1 2Next

External reference:

Show entries

Search:

ID	Source
003371	NDDF
10660	PUBCHEM_CID
151666	RXNORM
1568	MMSL
387469006	SNOMEDCT_US
4018048	VUID
4018048	VANDF
4605	MMSL
61	INN_ID
6646	MMSL

Showing 1 to 10 of 20 entries

Previous1 2Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Dimenhydrinate	HUMAN OTC DRUG LABEL	1	0904-6772	TABLET	50 mg	ORAL	OTC monograph final	16 sections
Dimenhydrinate	HUMAN OTC DRUG LABEL	1	0924-1007	TABLET	50 mg	ORAL	OTC monograph final	17 sections
Driminate	HUMAN OTC DRUG LABEL	1	0904-2051	TABLET	50 mg	ORAL	OTC monograph final	15 sections
Driminate	HUMAN OTC DRUG LABEL	1	0904-2051	TABLET	50 mg	ORAL	OTC monograph final	15 sections
Driminate	HUMAN OTC DRUG LABEL	1	0904-2051	TABLET	50 mg	ORAL	OTC monograph final	15 sections
Driminate	HUMAN OTC DRUG LABEL	1	0904-2051	TABLET	50 mg	ORAL	OTC monograph final	15 sections
Driminate	HUMAN OTC DRUG LABEL	1	0904-2051	TABLET	50 mg	ORAL	OTC monograph final	15 sections
Driminate	HUMAN OTC DRUG LABEL	1	0904-2051	TABLET	50 mg	ORAL	OTC monograph final	15 sections
Gravol	HUMAN OTC DRUG LABEL	1	10237-940	CAPSULE, LIQUID FILLED	50 mg	ORAL	OTC monograph final	15 sections
Gravol	HUMAN OTC DRUG LABEL	1	10237-941	TABLET, COATED	50 mg	ORAL	OTC monograph final	15 sections

Showing 1 to 10 of 30 entries

Previous1 2 3Next